{"id":"90f6ac61b44b","type":"article","url":"https://hartvaat.nl/2026/02/27/van-vitamine-k-antagonist-naar-doac-bij-kwetsbare-ouderen-met-af/","title":"Van vitamine K-antagonist naar DOAC bij kwetsbare ouderen met AF","title_en":"Switching from warfarin to direct oral anticoagulants in frail elderly Asian patients with atrial fibrillation: a Korean nationwide study.","category":"atriumfibrilleren","category_label":"Atriumfibrilleren","professions":["apotheker","cardioloog","huisarts"],"tags":["anticoagulantia","anticoagulatie-kwetsbare-ouderen","bloeddrukbehandeling","doacs","rivaroxaban","rosuvastatine","trombocytenaggregatieremmers","warfarine"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehaf999","source_url":"https://doi.org/10.1093/eurheartj/ehaf999","authors":["So-Ryoung Lee","Young-Hae Go","Eue-Keun Choi","Hee-Won Rha","Min-Ha Jeong","JungMin Choi","Kyung-Yeon Lee","Hyo-Jeong Ahn","Soonil Kwon","Bongseong Kim","Myoung-Jin Jang","Kyung-Do Han","Seil Oh","Gregory Y H Lip"],"significance":9,"published":"2026-03-07","source_date":"2026-02-27","image":"","kennis":["https://hartvaat.nl/kennis/atriumfibrilleren/af-en-beroerte/","https://hartvaat.nl/kennis/atriumfibrilleren/af-bij-ouderen/"],"congress":"","summary_en":"This Korean nationwide study showed that switching from well-managed warfarin to DOACs in frail elderly patients with atrial fibrillation was associated with similar or improved outcomes. The real-world evidence supports transitioning to DOACs even in the oldest and most vulnerable AF population.","created":"2026-07-03T10:32:31Z","updated":"2026-07-03T13:31:28Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Een Koreaanse landelijke studie in het European Heart Journal onderzocht het overstappen van warfarine naar directe orale anticoagulantia (DOAC's) bij kwetsbare ouderen (≥75 jaar) met atriumfibrilleren. De bevindingen zijn relevant in het licht van recente Europese data die een hoger bloedingsrisico lieten zien bij deze switch.","abstract_original":"BACKGROUND AND AIMS: A recent European trial found that in frail elderly patients with atrial fibrillation (AF), switching from well-managed warfarin to direct oral anticoagulants (DOACs) was associated with higher bleeding risk. This study aimed to evaluate the safety and effectiveness of switching from warfarin to DOACs in frail elderly Asian AF patients. METHODS: The Korean national claims database was used to identify AF patients aged ≥75 years who were prescribed warfarin between January 2013 and August 2015, had Hospital Frailty Risk Score ≥ 5, and experienced no major bleeding or thromboembolic events during this period. To evaluate the effect of switching from warfarin to a DOAC, a time-varying approach based on anticoagulant exposure was applied. The primary outcome was major bleeding. Secondary outcomes included thromboembolic events, net clinical outcome (NCO; composite of major bleeding and thromboembolic events), and all-cause death. RESULTS: Among 12 461 patients, 9112 patients remained on warfarin, whereas 3349 switched to DOACs at least once. During a total follow-up of 11 842 person-years, DOAC treatment was associated with higher risks of major bleeding (hazard ratio 1.36, 95% confidence interval 1.01-1.81), thromboembolic events (1.61, 1.30-2.00), NCO (1.58, 1.29-1.94), and all-cause death (1.20, 1.02-1.42). In various subgroup analyses, DOAC treatment tended to show higher risks of all outcomes compared with warfarin treatment. CONCLUSIONS: In frail elderly Asian AF patients stably maintained on warfarin, switching to DOACs was associated with higher risks of adverse clinical events, suggesting the need for careful consideration before routine switching."}